FAK inhibitor PF-573228 significantly reduced FAK activation in bleomycin-treated lungs (Fig. 4D, lanes 6–10 versus lanes 1–5), supporting that FAK inhibitor blocks FAK activation and attenuates lung fibrosis in animal model of lung fibrosis. Here, PTK2 is linked to pulmonary fibrosis.